Inhaltsverzeichnis
Auswahl der wissenschaftlichen Literatur zum Thema „Interleukin-12“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Interleukin-12" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Interleukin-12"
Leonard, Patricia, und Sanjiv Sur. „Interleukin-12“. BioDrugs 17, Nr. 1 (2003): 1–7. http://dx.doi.org/10.2165/00063030-200317010-00001.
Der volle Inhalt der Quelle&NA;. „Interleukin-12“. Inpharma Weekly &NA;, Nr. 1124 (Februar 1998): 7. http://dx.doi.org/10.2165/00128413-199811240-00013.
Der volle Inhalt der QuelleTrinchieri, Giorgio. „Interleukin-12“. Clinical Immunotherapeutics 3, Nr. 4 (April 1995): 262–70. http://dx.doi.org/10.1007/bf03259278.
Der volle Inhalt der QuelleClinton, Steven K., Eduardo Canto und Michael A. O'Donnell. „INTERLEUKIN-12“. Urologic Clinics of North America 27, Nr. 1 (Februar 2000): 147–55. http://dx.doi.org/10.1016/s0094-0143(05)70242-1.
Der volle Inhalt der QuelleWeiner, David. „Plasmid Interleukin 12“. AIDS 14, Nr. 12 (August 2000): 1759–60. http://dx.doi.org/10.1097/00002030-200008180-00010.
Der volle Inhalt der QuelleLeng, S. X., und J. A. Elias. „Interleukin-11 inhibits macrophage interleukin-12 production.“ Journal of Immunology 159, Nr. 5 (01.09.1997): 2161–68. http://dx.doi.org/10.4049/jimmunol.159.5.2161.
Der volle Inhalt der QuelleFox, Robert J., und Abdolmohamad M. Rostami. „Anti???Interleukin-12 Antibody“. BioDrugs 13, Nr. 4 (April 2000): 233–41. http://dx.doi.org/10.2165/00063030-200013040-00002.
Der volle Inhalt der Quelle&NA;. „Interleukin-12 trial halted“. Reactions Weekly &NA;, Nr. 556 (Juni 1995): 2. http://dx.doi.org/10.2165/00128415-199505560-00003.
Der volle Inhalt der Quelle&NA;. „Interleukin-12 studies continue“. Reactions Weekly &NA;, Nr. 558 (Juli 1995): 2. http://dx.doi.org/10.2165/00128415-199505580-00003.
Der volle Inhalt der Quelle&NA;. „Interleukin-12 trial halted“. Inpharma Weekly &NA;, Nr. 992 (Juni 1995): 21. http://dx.doi.org/10.2165/00128413-199509920-00047.
Der volle Inhalt der QuelleDissertationen zum Thema "Interleukin-12"
Balu, Sucharitha. „Cloning and characterisation of chicken interleukin-12 and the interleukin-12 receptor“. Thesis, University of Bristol, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.419213.
Der volle Inhalt der QuelleSwinburne, Sarah Jane. „A study of the molecular and biological characteristics of ovine interleukin-12“. Title page, contents and summary only, 2000. http://web4.library.adelaide.edu.au/theses/09PH/09phs9777.pdf.
Der volle Inhalt der QuelleWerner, Christoph. „Von Interleukin-12 zur p40-Zytokinfamilie Interleukin-12-unabhängige Wirkungen von p40-Zytokinen in der Infekt- und Tumorabwehr /“. [S.l.] : [s.n.], 2003. http://dol.uni-leipzig.de/pub/2003-34.
Der volle Inhalt der QuelleWerner, Christoph. „Von Interleukin-12 zur p40-Zytokinfamilie: Interleukin-12-unabhängige Wirkungen von p40-Zytokinen in der Infekt- und Tumorabwehr“. Doctoral thesis, Universitätsbibliothek Leipzig, 2004. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-37550.
Der volle Inhalt der QuelleInterleukin-12 (IL-12) is a key cytokine in the development of a protective cellular Th1 immune response. It consists of a p40 and a p35 subunit. Following stimulation with IL-12, NK and T cells produce large amounts of IFN-gamma resulting in a type 1 immune response. The p40 subunit of IL-12 is also part of other biologically active proteins such as monomeric or homodimeric p40 or the heterodimeric IL-23 (in combination with a p19 subunit). While in this study the homodimeric p40 appears to antagonize IL-12, IL-23 was demonstrated to have agonistic effects. The aim of this study was to investigate p40-dependent effects which can be observed independently of IL-12, i.e. potential effects mediated by IL-23. For the experiments mutant mice were used so that IL-12 dependent mechanisms could not play a role but only p40-dependent proteins excluding IL-12. In a Salmonella Enteritidis infection model p35-gene deleted (p35-/-) and p40-/- mice were used. As the expression of p40 is induced by bacterial antigen, differences between the strains were caused by the p40 protein. During the infection p40 proteins induced IFN-gamma production thus improving the killing of intracellular pathogens. This resulted in a better control of the systemic infection and longer survival periods of the p35-/- mice as compared to p40-/- mice. For the experiments in the tumor model using the Lewis-Lung carcinoma and the Melanoma B16 as tumors, p35/40-/- mice which are unable to produce any p40 proteins, received gene therapy with DNA encoding for p40. This local gene therapy resulted in a reduced tumor growth. Immunohistochemical examination revealed an infiltration of the tumor tissue with macrophages and a reduced neoangiogenesis within the tumor. This effect could not be achieved by local administration of IL-23 or the p40-homodimer as a protein, indicating the existence of an as yet unknown heterodimeric p40 protein. In vitro experiments showed that IL-23 induces IFN-gamma production by splenocytes and this effect can be antagonized by the homodimer. Interestingly, IL-23 is also able to antagonize IL-12 in primary splenocyte cultures. In vitro infection with Salmonella resulted in an p40-dependent IFN-gamma production that could also be antagonized by the homodimer. The protective effects in the infection model might be caused by IL-23, which is supported by the in vitro results. On the other hand, in the tumor model IL-23 does not seem to be the player and it must be concluded that the protective effects are caused by an other as yet unknown p40-dependent protein p40-x
Walter, Claudia. „Bestimmung der Zytokine Interleukin-1ra, Interleukin-6, Interleukin-10 und Interleukin-12 im Vaginalsekret bei Frauen mit Bakterieller Vaginose“. Diss., lmu, 2004. http://nbn-resolving.de/urn:nbn:de:bvb:19-28461.
Der volle Inhalt der QuelleChakir, Habiba. „Role of interleukin-12 and interleukin-18 in murine immune cell regulation“. Thesis, University of Ottawa (Canada), 2003. http://hdl.handle.net/10393/28980.
Der volle Inhalt der QuelleRempel, Julia D. „Interleukin-12 and interleukin-10 regulation of antibody responses upon protein antigen immunization“. Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1999. http://www.collectionscanada.ca/obj/s4/f2/dsk2/ftp02/NQ41623.pdf.
Der volle Inhalt der QuelleAthie, Morales Veronica. „Interleukin 12 signalling pathways in human T lymphocytes“. Thesis, University College London (University of London), 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.249566.
Der volle Inhalt der QuelleSchardt, Victor. „Vergleichende Untersuchungen zur Hefepilzbesiedelung von Mundhöhle und Vagina und Bestimmung von Interleukin-4, Interleukin-10 und Interleukin-12“. Diss., lmu, 2013. http://nbn-resolving.de/urn:nbn:de:bvb:19-155152.
Der volle Inhalt der QuelleNaseer, Tanveer 1971. „In vivo expression of interleukin-12 and interleukin-13 in the pathogenesis of asthma“. Thesis, McGill University, 1996. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=23925.
Der volle Inhalt der QuelleBücher zum Thema "Interleukin-12"
Lasek, Witold, und Radoslaw Zagozdzon. Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-46906-5.
Der volle Inhalt der QuelleIl-12 (Chemical Immunology). S. Karger AG (Switzerland), 1997.
Den vollen Inhalt der Quelle findenInterleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. Springer International Publishing AG, 2016.
Den vollen Inhalt der Quelle findenLasek, Witold, Radoslaw Zagozdzon und Marek Jakóbisiak. Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology. Springer, 2016.
Den vollen Inhalt der Quelle findenInterleukin 12: Cellular and molecular immunology of an important regulatory cytokine. New York, N.Y: New York Academy of Sciences, 1996.
Den vollen Inhalt der Quelle findenNew York Academy of Sciences (Corporate Author), Inc. Genetics Institute (Corporate Author) und Michael T. Lotze (Editor), Hrsg. Interleukin 12: Cellular and Molecular Immunology of an Important Regulatory Cytokine (Annals of the New York Academy of Sciences, V. 795). New York Academy of Sciences, 1996.
Den vollen Inhalt der Quelle finden(Editor), Michael T. Lotze, Giorgio Trinchiere (Editor), Maurice Gately (Editor) und Stanley Wolf (Editor), Hrsg. Interleukin 12: Cellular and Molecular Immunology of an Important Regulatory Cytokine (Annals of the New York Academy of Sciences). New York Academy of Sciences, 1996.
Den vollen Inhalt der Quelle findenConstruction of murine interleukin-12 retroviral Vectors: Implications for gene therapy of hematologic malignancies. Ottawa: National Library of Canada, 1996.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "Interleukin-12"
Kaufman, Howard L., und Neal Dharmadhikari. „Interleukin-12“. In Cancer Therapeutic Targets, 345–59. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4419-0717-2_144.
Der volle Inhalt der QuelleDieckman, Tessa, Antonie Zwiers, Georg Kraal und Gerd Bouma. „Interleukin 12“. In Compendium of Inflammatory Diseases, 709–14. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_220.
Der volle Inhalt der QuelleBukowski, Ronald M., und Charles Tannenbaum. „Interleukin-12“. In Melanoma, 221–34. Totowa, NJ: Humana Press, 2002. http://dx.doi.org/10.1007/978-1-59259-159-6_8.
Der volle Inhalt der QuelleKaufman, Howard L., und Neal Dharmadhikari. „Interleukin-12“. In Cancer Therapeutic Targets, 1–15. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4614-6613-0_144-1.
Der volle Inhalt der QuelleDieckman, Tessa, Antonie Zwiers, Georg Kraal und Gerd Bouma. „Interleukin 12“. In Encyclopedia of Inflammatory Diseases, 1–7. Basel: Springer Basel, 2014. http://dx.doi.org/10.1007/978-3-0348-0620-6_220-1.
Der volle Inhalt der QuelleBryan, Shannon, Michiko Kobayashi und Sanjiv Sur. „Interleukin-12, Interleukin-18 and Interferon-γ“. In New Drugs for Asthma, Allergy and COPD, 274–78. Basel: KARGER, 2001. http://dx.doi.org/10.1159/000062155.
Der volle Inhalt der QuellePile, Kevin D., Garry G. Graham und Stephen M. Mahler. „Interleukin-12/23 Inhibitors: Ustekinumab“. In Compendium of Inflammatory Diseases, 714–17. Basel: Springer Basel, 2016. http://dx.doi.org/10.1007/978-3-7643-8550-7_232.
Der volle Inhalt der QuellePile, Kevin D., Garry G. Graham und Stephen M. Mahler. „Interleukin-12/23 Inhibitors: Ustekinumab“. In Encyclopedia of Inflammatory Diseases, 1–3. Basel: Springer Basel, 2015. http://dx.doi.org/10.1007/978-3-0348-0620-6_232-1.
Der volle Inhalt der QuelleAulitzky, W. E., und C. Huber. „Interleukin-12: Biology and Clinical Studies“. In Symposium in Immunology VI, 111–23. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60562-8_10.
Der volle Inhalt der QuelleFernández-Ruiz, Mario. „Interleukin-12 and -23 Targeted Agents“. In Infectious Complications in Biologic and Targeted Therapies, 199–217. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11363-5_11.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Interleukin-12"
„03 Targeting interleukin 12/23“. In 8th ANNUAL MEETING OF THE LUPUS ACADEMY, Warsaw, Poland, September 6–8, 2019. Lupus Foundation of America, 2019. http://dx.doi.org/10.1136/lupus-2019-la.15.
Der volle Inhalt der QuelleConway, R., L. O’Neill, P. Gallagher, G. McCarthy, C. Murphy, D. Veale, U. Fearon und E. Molloy. „SAT0542 Interleukin-12 and interleukin-23 are key pathogenic players in giant cell arteritis“. In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.2850.
Der volle Inhalt der QuelleCanataroglu, A., E. Erken und R. Gunesacar. „FRI0165 Serum levels of interleukin-12 in behcet’s disease“. In Annual European Congress of Rheumatology, Annals of the rheumatic diseases ARD July 2001. BMJ Publishing Group Ltd and European League Against Rheumatism, 2001. http://dx.doi.org/10.1136/annrheumdis-2001.225.
Der volle Inhalt der QuelleVo, Jimmy Nhu. „Abstract 1535: Intratumoral chitosan/interleukin-12 immunotherapy reduces breast cancer metastasis“. In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1535.
Der volle Inhalt der QuelleUrsic Valentinuzzi, K., U. Kamensek, S. Kos, S. Kranjc Brezar, M. Cemazar und G. Sersa. „P08.03 Interleukin-12 gene electrotransfer as an adjuvant immunotherapy to electrochemotherapy“. In iTOC9 – 9th Immunotherapy of Cancer Conference, September 22–24, 2022 – Munich, Germany. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-itoc9.49.
Der volle Inhalt der QuelleIshihara, Jun, Aslan Mansurov und Jeffrey Hubbell. „1227 Eliminating the immunotoxicity of interleukin-12 through protease-sensitive masking“. In SITC 37th Annual Meeting (SITC 2022) Abstracts. BMJ Publishing Group Ltd, 2022. http://dx.doi.org/10.1136/jitc-2022-sitc2022.1227.
Der volle Inhalt der QuelleSmith, Sean, Jack Baltz, Bhanu Koppolu, Sruthi Ravindranathan, Khue Nguyen und David Zaharoff. „Abstract B020: Effector cells in chitosan/interleukin-12 immunotherapy of bladder tumors in mice“. In Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr15-b020.
Der volle Inhalt der QuelleYang, Xi, Ashlee Tietje, Xianzhong Yu und Yanzhang Wei. „Abstract 4874: Interleukin-12/FasTI: A novel bi-functional fusion protein for cancer immunotherapy“. In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4874.
Der volle Inhalt der QuelleCheema, Tooba A., Hiroaki Wakimoto, Samuel Rabkin und Robert L. Martuza. „Abstract 5389: Oncolytic herpes simplex virus expressing interleukin-12 for treating glioma stem cells“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-5389.
Der volle Inhalt der QuelleSimkin, Guillermo O., Julia G. Levy und David W. C. Hunt. „Interleukin-12 reverses the inhibitory impact of photodynamic therapy (PDT) on the murine contact hypersensitivity response“. In BiOS '98 International Biomedical Optics Symposium, herausgegeben von Thomas J. Dougherty. SPIE, 1998. http://dx.doi.org/10.1117/12.308134.
Der volle Inhalt der QuelleYou might want to see the page in this language: English.